Transition supports continuity of supply and aligns ialuril® with IBSA’s expanding UK uro-gynaecology portfolio. Watford, UK. April 9th, 2026 – IBSA UK&I, the UK subsidiary of Swiss pharmaceutical company IBSA, today announces that it will assume direct responsibility for the commercialisation and distribution of ialuril® in the United Kingdom and
A next-generation hyaluronic acid treatment designed to improve sexual and genital symptoms of GSM Watford, UK. February 2nd 2026 – IBSA UK, the UK subsidiary of Swiss pharmaceutical company IBSA, today announces the launch of Hyaluxelle®, a non-hormonal hyaluronic acid treatment indicated for adult women to treat vulvar vestibule atrophic
A clinically supported option for early intervention in a historically underdiagnosed and undertreated condition. WATFORD, UK. February 2nd, 2026 – IBSA UK&I has today announced the launch of Perovial®, the first licensed hyaluronic acid injectable indicated for the management of Peyronie’s disease (PD) in its acute phase. Perovial® offers healthcare